Key Takeaways:
PROCEPT BioRobotics Corp. faces a securities fraud class action alleging it concealed a discount program that inflated handpiece sales, causing an 18% stock decline when disclosed, according to a lawsuit filed in the U.S. District Court for the Northern District of California.
"The company's undisclosed discount program artificially inflated reported U.S. handpiece unit sales by pulling forward demand at the expense of future periods," the complaint states. The lawsuit, filed by Bleichmar Fonti & Auld LLP, seeks lead plaintiff status for investors who bought shares between Feb. 28, 2024 and Feb. 25, 2026.
Procept, which makes robotic surgical devices for enlarged prostate treatment, reported on Feb. 25, 2026 that U.S. handpiece unit sales had exceeded procedures in every quarter since Q1 2023, creating excess field inventory of more than 10,000 units. The company also said fourth-quarter U.S. handpiece sales fell about 30% to roughly 9,400 units. Shares dropped $5.15 over two days to $22.69.
The alleged scheme unraveled over three earnings disclosures. On Aug. 6, 2025, Procept forecast about 13,350 handpiece shipments for the following quarter, well below consensus, sending shares down 16% over two days. On Nov. 4, 2025, the company cut annual handpiece guidance by 1,000 units and acknowledged customers were "probably carrying too much" inventory, triggering a 10% decline. The Feb. 25, 2026 disclosure revealed the full extent of the overhang and the elimination of the discount program that had encouraged bulk purchases near quarter-end.
The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Investors have until Sept. 22, 2026 to seek lead plaintiff appointment. The case is captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, et al., No. 26-cv-7691.
The lawsuit adds legal and reputational risk for Procept as it works through the inventory glut. The company's next quarterly report will show whether handpiece sales align with procedure volumes without the discount program, a key metric for investors assessing the scope of the recovery.
This article is for informational purposes only and does not constitute investment advice.
